Replies

FROM THE LINK PROVIDED IN THE ARTICLE:

We enrolled 36 out of 42 patients meeting the inclusion criteria in this study that had at least
six days of follow-up at the time of the present analysis.

A total of 26 patients received
hydroxychloroquine and 16 were control patients.

Six hydroxychloroquine-treated patients
were lost in follow-up during the survey because of early cessation of treatment. Reasons are as follows:

* three patients were transferred to intensive care unit, including one transferred on day2 post-inclusion who was PCR-positive on day1,

* one transferred on day3 post-inclusion who was PCR-positive on days1-2 and

* one transferred on day4 post-inclusion who was PCR-positive on day1 and day3;

* one patient died on day3 post inclusion and was PCR-negative on day2;

* one patient decided to leave the hospital on day3 post-inclusion and was PCR-negative on days1-2;

* finally, one patient stopped the treatment on day3 post-inclusion because of nausea and was PCR-positive on days1-2-3.

The results presented here are therefore those of
36 patients (20 hydroxychloroquine-treated patients and 16 control patients). None of the control patients was lost in follow-up.

Basic demographics and clinical status are presented in
Table 1. Overall, 15 patients were male (41.7%), with a mean age of 45.1 years. The proportion of asymptomatic patients was 16.7%, that of patients with URTI symptoms was 61.1% and that of patients with LRTI symptoms was 22.2%).

All patients with LRTI symptoms, had confirmed pneumonia by CTScan. Hydroxychloroquine-treated patients were
older than control patients (51.2 years vs. 37.3 years).

No significant difference was observed
between hydroxychloroquine-treated patients and control patients with regard to gender, clinical status and duration of symptoms prior to inclusion (Table 1).